Glenmark Pharmaceuticals Ltd announced today the launch of AKYNZEO I.V, a drug used to prevent chemotherapy-induced nausea and vomiting, in India and Nepal through an exclusive licencing agreement with Helsinn, a Swiss biopharma company...
Bharat Biotech's CMD Krishna Ella said on Saturday that the company's intranasal COVID-19 vaccine iNCOVACC will be available on January 26...
On the lines of its Production Linked Incentive (PLI) scheme, government of India is mulling a Research Linked Incentive (RLI) programme to galvanize pharmaceutical research for development of biotechnology products, said Dr V G Somani
Dr Reddy's Laboratories said it has successfully completed the full set of clinical studies of its proposed rituximab biosimilar candidate, 'DRL_RI' for filing in highly regulated markets such as the US, Europe and other regions...
Sun Pharmaceutical Industries Limited, India's largest drugmaker, said it will acquire U.S.-based Concert Pharmaceuticals for $576 million in cash to gain access to its experimental drug for treating patchy baldness...
Alembic Pharmaceuticals Limited, an R&D pharmaceutical firm, announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Acalabrutinib Capsules, 100 mg, used for...
Calibre Scientific, a global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics, industrial, and biopharmaceutical communities, has announced the acquisition of Glass Chemicals, a Spanish...
Cipla, a pharmaceutical company, announced the launch of a diagnostic device for a variety of conditions such as diabetes, infectious diseases, and thyroid function. Cippoint, a point-of-care testing device, offers a wide range of testing...
Sebi has approved pharmaceutical companies Innova Captab Ltd and Blue Jet Healthcare to raise funds through an initial public offering (IPO). According to an update with Sebi, the two firms that filed their preliminary papers with Sebi between...
Glenmark Pharmaceuticals Ltd. has introduced'sacubitril + valsartan' tablets in India, which are indicated for patients with chronic heart failure (NYHA class II-IV) and a low ejection fraction (HFrEF). It is marketed as 'Sacu VTM' and must be...
, CDSCO.jpg)
